LINCOLN, Mass., April 19, 2016 /PRNewswire/ -- Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling to drug development, is pleased to announce that Dr. John Burke will attend and present an immuno-oncology poster at the 2016 American Association for Cancer Research (AACR) Annual Meeting. This year's AACR Annual Meeting occurs April 16-20, 2016 in New Orleans, LA.
Dr. John Burke, PhD, Co-Founder, President, and CEO of Applied BioMath, will present Applied BioMath's recent work in immuno-oncology with a poster entitled "Quantitative systems pharmacology modeling and analysis provides biological insights into anti-PD-1 dosing and predicts optimal PD-1 x TIM-3 therapeutic properties for bispecifics and fixed dose combinations in immuno-oncology." This example highlights how developing and interrogating a quantitative systems pharmacology model (QSPM) of PD-1 and TIM-3 provided:
- Biological insights by predicting why dosing regimens are quite similar for two therapeutics targeting PD-1 that have affinities that differ by several orders of magnitude
- Best-in-class profile predictions for PD-1 and TIM-3 dual antagonists
"Each year the AACR Annual Meeting assembles the best of the best in cancer research. I am privileged to have our work included among such distinguished and exciting research."
Dr. John Burke, PhD, Co-Founder, President, and CEO of Applied BioMath
This immuno-oncology case study was recently featured as part of a Quantitative Systems Pharmacology Modeling (QSPM) webinar, available on-demand at www.appliedbiomath.com/webinars.
About Applied BioMath
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling to drug development, helps biotechnology and pharmaceutical companies answer complex, critical Go/No-go decisions in R&D. Applied BioMath leverages biology, proprietary technology, high-performance computing, and decades of industry experience to help groups better understand their candidate, its best-in-class parameters, competitive advantages, and the best path forward. Our involvement shortens project timelines, lowers cost, and increases the likelihood of a best-in-class drug. We provide clarity to complex situations, answer otherwise unanswerable questions, and our approach, when validated in the clinic, is 10x more accurate than traditional methodologies.
Applied BioMath and the Applied BioMath logo are trademarks of Applied BioMath, LLC.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/applied-biomath-llc-to-present-an-immuno-oncology-case-study-at-the-2016-aacr-annual-meeting-300253830.html
SOURCE Applied BioMath